These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35420123)

  • 61. Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon.
    Noeske J; Voelz N; Fon E; Abena Foe JL
    BMC Res Notes; 2012 Mar; 5():160. PubMed ID: 22436423
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
    Han X; Chen X; Sha W; Zhang X; Qiu L; Wang J; Wu G; Yao L; Lv Y; Zhang X; Zhou J; Tang S; Chu N
    Int J Tuberc Lung Dis; 2020 Aug; 24(8):789-794. PubMed ID: 32912383
    [No Abstract]   [Full Text] [Related]  

  • 63. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
    Schnippel K; Ndjeka N; Maartens G; Meintjes G; Master I; Ismail N; Hughes J; Ferreira H; Padanilam X; Romero R; Te Riele J; Conradie F
    Lancet Respir Med; 2018 Sep; 6(9):699-706. PubMed ID: 30001994
    [TBL] [Abstract][Full Text] [Related]  

  • 65. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Management of rifampicin-resistant tuberculosis in conflict-affected areas: The case of Iraq.
    Tesfahun HM; Al-Salihi L; Abdulkareem Al-Ani N; Mankhi AA; Mohammed A; Lim CAE; Al-Hilfi RA; Jouego CG; Decroo T; Moussally K; Ferlazzo G; Isaakidis P
    PLoS One; 2024; 19(1):e0296952. PubMed ID: 38241233
    [TBL] [Abstract][Full Text] [Related]  

  • 67. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
    Van Deun A; Decroo T; Tahseen S; Trébucq A; Schwoebel V; Ortuno-Gutierrez N; de Jong BC; Rieder HL; Piubello A; Chiang CY
    Int J Antimicrob Agents; 2020 Jan; 55(1):105822. PubMed ID: 31626907
    [TBL] [Abstract][Full Text] [Related]  

  • 68. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
    Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
    BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [The therapeutic effect of regimens containing isoniazid and rifampicin for pulmonary tuberculosis with single isoniazid or rifampicin resistance].
    Tan S; Ding X; Tan Y; Cai X; Li Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):915-8. PubMed ID: 25609129
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
    Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
    BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
    Perrineau S; Lachâtre M; Lê MP; Rioux C; Loubet P; Fréchet-Jachym M; Gonzales MC; Grall N; Bouvet E; Veziris N; Yazdanpanah Y; Peytavin G
    Int J Tuberc Lung Dis; 2019 Jan; 23(1):99-104. PubMed ID: 30674381
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data.
    Darmayani IGAAPS; Ascobat P; Instiaty I; Sugiri YJR; Sawitri N
    Acta Med Indones; 2022 Jul; 54(3):389-396. PubMed ID: 36156479
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini.
    Vambe D; Kay AW; Furin J; Howard AA; Dlamini T; Dlamini N; Shabangu A; Hassen F; Masuku S; Maha O; Wawa C; Mafukidze A; Altaye K; Sikhondze W; Gwitima T; Keus K; Simelane T; Kerschberger B
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1095-1102. PubMed ID: 33126945
    [No Abstract]   [Full Text] [Related]  

  • 76. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes.
    Kritski AL; Rodrigues de Jesus LS; Andrade MK; Werneck-Barroso E; Vieira MA; Haffner A; Riley LW
    Chest; 1997 May; 111(5):1162-7. PubMed ID: 9149564
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam.
    Lan NTN ; Lademarco MF; Binkin NJ; Tung LB; Quy HT; Cĵ NV
    Int J Tuberc Lung Dis; 2001 Jun; 5(6):575-8. PubMed ID: 11409587
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis.
    Gegia M; Winters N; Benedetti A; van Soolingen D; Menzies D
    Lancet Infect Dis; 2017 Feb; 17(2):223-234. PubMed ID: 27865891
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
    Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A non-randomized pragmatic historically controlled trial evaluating the effectiveness and safety of a bedaquiline or a linezolid-based short regimen for rifampicin-resistant tuberculosis.
    Martínez-Campreciós J; Aznar ML; Zacarias A; Terán R; Nindia A; Espinosa-Pereiro J; Aixut S; Ramos ME; Nicolau MJ; Sulleiro E; Tórtola MT; Sánchez-Montalvá A; Molina I
    J Infect; 2024 Dec; 89(6):106291. PubMed ID: 39426632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.